scholarly journals COMBINATION IMMUNOTHERAPY IN METASTATIC RENAL CELL CARCINOMA

2021 ◽  
Vol 01 (01) ◽  
pp. 86
Author(s):  
P. Sepe ◽  
A. Ottini ◽  
E. Verzoni ◽  
V. Guadalupi ◽  
M. Claps ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Combination Immunotherapy

Successful Response to Nivolumab Plus Ipilimumab Therapy in a Hemodialysis Patient With Metastatic Renal Cell Carcinoma

2021 ◽  
Vol 1 (3) ◽  
pp. 207-211
Author(s):  
HIROSHI MASUDA ◽  
KOSUKE MIKAMI ◽  
KOTARO OTSUKA ◽  
KYOKUSIN HOU ◽  
TAKAHITO SUYAMA ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Hemodialysis Patient ◽  
Pulse Therapy ◽  
Hemodialysis Patients ◽  
Combination Immunotherapy ◽  
Efficacy And Safety ◽  
Steroid Pulse

Background/Aim: There are few reports about the administration of nivolumab plus ipilimumab to hemodialysis patients and their efficacy and safety have not been established yet. Case Report: A 74-year-old male, who was receiving hemodialysis, was presented with metastatic renal cell carcinoma (mRCC). Two years later, more metastases were found, hence, immunotherapy involving nivolumab plus ipilimumab was initiated. After two doses of immunotherapy, interstitial pneumonia was observed. Thus, steroid pulse therapy was administered immediately. Subsequently, computed tomography (CT) findings and symptoms improved markedly. One month later, a CT scan showed a nodular shadow and an air cavity. A fungal infection was strongly suspected, so an antifungal drug was administered. Conclusion: Combination immunotherapy with nivolumab plus ipilimumab was demonstrated to be effective in a hemodialysis patient with mRCC.

scholarly journals Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?

2018 ◽  
Vol 14 (29) ◽  
pp. 2997-2999 ◽  
Author(s):  
Vincenzo Di Nunno ◽  
Lidia Gatto ◽  
Benedetta Fragomeno ◽  
Marta Cubelli ◽  
Elisabetta Nobili ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Combination Immunotherapy

scholarly journals Experience of using 1st line combination immunotherapy in patients with metastatic renal cell carcinoma

2021 ◽  
Vol 17 (3) ◽  
pp. 47-63
Author(s):  
A. S. Kalpinskiy ◽  
I. V. Myslevtsev ◽  
A. N. Andrianov ◽  
K. M. Nyushko ◽  
M. P. Golovashchenko ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Combination Immunotherapy ◽  
Free Survival ◽  
Recist 1.1 ◽  
Best Response

The study objective is to evaluate effectiveness and tolerability of 1st line combination immuno-oncological therapy with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma (mRCC) in clinical practice.Materials and methods. The study included 38 patients with mRCC who received combination immunotherapy between July of 2019 and September of 2021. Median follow-up duration was 8 (2-25) months. Mean age of the patients was 58.3 (20-85) years. Previously 22 (57.9 %) patients underwent surgical treatment. Unfavorable physical status 2-3 per the ECOG scale was observed in 10 (26.3 %) patients. Clear-cell type of renal cell carcinoma was diagnosed in 34 (89.6 %) patients, non-clear-cell types in 4 (10.4 %). Sarcomatoid component in the tumor was detected in 8 (21.0 %) patients. G3-4 mRCC variant was verified in 16 (42.1 %) patients. Poor prognosis per the IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) scale was identified in 16 (42.1 %) patients, intermediate -in 20 (52.6 %) patients. All 4 administrations of combination immunotherapy were received by 29 (76.3 %) patients.Results. For median follow-up duration of 8 (2-25) months, 23 (60.5 %) patients continue treatment, 15 (39.5 %) completed therapy with nivolumab and ipilimumab due to various reasons including progression in 11 (28.9 %), death in 2 (5.3 %), intolerable toxicity in 2 (5.3 %) cases. Median duration of combination immunotherapy was 9 (2-24) months. Subsequent antitumor therapy was administered to 3 (7.9 %) patients. During induction course immune-mediated adverse event (grade III-IV hepatitis) developed in 3 (7.9 %) patients. Adverse events were observed in 81.6 % of patients, including grade III-IV in 23.7 % of patients. Objective response was observed in 44.8 % of cases, complete response in 5.3 % of cases, partial response in 39.5 % of cases; controlled disease was achieved in 84.3 % of patients. Median progression-free survival and overall survival were 8 months.Conclusion. In our study despite large number of patients with poor prognosis and poorly differentiated tumors, 64.0 % of patients are alive and 60.5 % of patients continue treatment without disease progression after 18 months of combination immunotherapy. Progression-free survival was significantly affected by sarcomatoid component in the tumor, number of unfavorable factors per the IMDC scale, best response per RECIST 1.1; overall survival was significantly affected by sarcomatoid component in the tumor, sum of measurable lesions, number of unfavorable factors per the IMDC scale, best response per RECIST 1.1, and presence of symptomatic metastases in the brain.

1103: Laparoscopic Salvage Nephrectomy after Targeted Neoadjuvant Therapy for Metastatic Renal Cell Carcinoma: Initial Results

2007 ◽  
Vol 177 (4S) ◽  
pp. 364-364 ◽  
Author(s):  
Surena F. Matin ◽  
Christopher G. Wood ◽  
Shi-Ming Tu ◽  
Nizar M. Tannir ◽  
Eric Jonasch
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Neoadjuvant Therapy ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Initial Results

637: Establishing a Porcine Model for the Accelerated Development of Cancer Vaccines for Patients with Metastatic Renal Cell Carcinoma

2005 ◽  
Vol 173 (4S) ◽  
pp. 173-174
Author(s):  
Quinton V. Cancel ◽  
Benjamin K. Yang ◽  
Zhen Su ◽  
Jens Dannull ◽  
Philipp Dahm ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Cancer Vaccines ◽  
Porcine Model

1716: Pharmaco-Angio-CT is Superior to 4 Phase Helical CT in the Detection of Recurrent Metastatic Renal Cell Carcinoma

2006 ◽  
Vol 175 (4S) ◽  
pp. 551-552
Author(s):  
Erich K. Lang ◽  
Richard J. Macchia ◽  
Raju Thomas ◽  
Ronald Davis ◽  
Douglas Slakey ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Helical Ct ◽  
Angio Ct

396: HSP27 Expression in Primary and Metastatic Renal Cell Carcinoma

2006 ◽  
Vol 175 (4S) ◽  
pp. 129-129
Author(s):  
Richard E. Zigeuner ◽  
Nikolaus Droschl ◽  
Volkmar Tauber ◽  
Peter Rehak ◽  
Cord Langner
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Hsp27 Expression
Sign in / Sign up

Export Citation Format

Share Document